You will be shown an abstract from a biomedical research paper. Given this abstract, your task is to extract all unique entities of the following types: ["Outcome", "Participant", "Intervention"].

Please return the output as a JSON object of the format: {"Participant" : ["patients with COPD", ...], "Intervention" : ["Atenolol", ...], "Outcome" : ["blood pressure", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Efficacy screening trials of paroxetine , pentoxifylline , riluzole , pramipexole and venlafaxine in cocaine dependence . AIMS The two studies presented here were conducted to assess the efficacy of paroxetine , pentoxifylline , riluzole , venlafaxine and pramipexole as medications for the treatment of cocaine dependence . DESIGN A multi-arm , modified blinded , placebo-controlled design was used . SETTING The studies were conducted at the Boston VA Healthcare System and the Boston University School of Medicine Medication Development Research Unit ( MDRU ) . PARTICIPANTS Participants met criteria for cocaine dependence during a 2-week screening period . INTERVENTION Following random assignment to one of the treatment groups , subjects received active medication or placebo for 8 weeks in combination with cognitive behavioral counseling . In the first study the efficacy of the antidepressant paroxetine ( 20 mg daily ) , the phosphodiesterase inhibitor pentoxifylline ( 1200 mg daily ) and the glutamate release inhibitor riluzole ( 100 mg daily ) was assessed . The antidepressant venlafaxine ( 150 mg daily ) and the dopamine agonist pramipexole ( 1.5 mg daily ) were evaluated in the second study . MEASUREMENTS Urine benzoylecgonine ( BE ) concentrations , self-report of cocaine use and global impression scores served as primary outcome measures . Secondary measures included assessments of cocaine craving and psychiatric functioning . Adverse events were monitored during the treatment period . FINDINGS None of the active medications produced greater reductions in urine BE concentrations over the treatment period than did placebo . There were trends for BE levels to become reduced in the pentoxifylline group during the first 4 weeks of treatment and for Addiction Severity Index ( ASI ) drug composite scores to be lower in the pentoxyfylline group at end-point compared to the placebo group . Significant within-group reductions in reported cocaine use and craving were found for all treatment groups , but none of the active medications were superior to placebo on these measures . The accuracy of self-reported cocaine use declined over the study period . Overall , the active medications were well tolerated . CONCLUSIONS This study does not support the use of paroxetine , pentoxifylline , riluzole , venlafaxine or pramipexole for the treatment of cocaine dependence . However , these results need to be interpreted with caution because of the small size and lack of homogeneity of the experimental groups .
{"Intervention": ["active medication", "placebo", "antidepressant venlafaxine", "riluzole", "phosphodiesterase inhibitor pentoxifylline", "pramipexole", "cognitive behavioral counseling", "pentoxifylline", "antidepressant paroxetine", "dopamine agonist pramipexole", "placebo-controlled", "paroxetine", "venlafaxine", "pentoxyfylline", "glutamate release inhibitor riluzole"], "Outcome": ["Urine benzoylecgonine ( BE ) concentrations", "efficacy", "global impression scores", "Addiction Severity Index ( ASI )", "self-reported cocaine use", "tolerated", "psychiatric functioning", "self-report of cocaine use", "Adverse events", "urine BE concentrations", "cocaine use and craving", "Efficacy", "BE levels", "assessments of cocaine craving"], "Participant": []}